and management of veno-occlusive disease (sinusoidal obstruction syndrome) following haematopoietic stem cell transplantation. British Journal of Haematology, 163 (4), 444–457. doi:10.1111/bjh.12558 Dine, J., Gordon, R., Shames, Y., Kasler, M. K. e Barton-Burke, M. (2017). Inibidores de checkpoints imunológicos: An innovation in immunotherapy for the treatment and management of patients with cancer. Asia-Pacific Journal of Oncology Nursing, 4(2), 127–135. doi:10.4103/apjon.apjon_4_17 Diouf, B., Crews, K. R., Lew, G., Pei, D., Cheng, C., Bao, J., . . . Evans, W. E. (2015). Association of an inherited genetic variant with vincristine- related peripheral neuropathy in children with acute lymphoblastic leukemia. Journal of the American Medical Association, 313 (8), 815– 823. doi:10.1001/jama.2015.0894 Dobrozsi, S., Yan, K., Hoffmann, R. e Panepinto, J. (2017). Patient- reported health status during pediatric cancer treatment. Pediatric Blood and Cancer, 64 (4), e1–e9. doi:10.1002/pbc.26295 Drew, B. J., Ackerman, M. J., Funk, M., Gibler, W. B., Kligfield, P., Menon, V., . . . Zareba, W. (2010). Prevention of torsade de pointes in hospital settings: A scientific statement from the American Heart Association and the American College of Cardiology Foundation. Journal of the American College of Cardiology, 55 (9), 934–947. doi:10.1016/j. jacc.2010.01.001 Drozdowicz, L. B. e Bostwick, J. M. (2014). Psychiatric adverse effects of pediatric corticosteroid use. Mayo Clinic Proceedings, 89 (6), 817–834. doi:10.1016/mayocp.2014.01.010 Duggin, K., Tickle, K., Norman, G., Yang, J., Wang, C., Cross, S., . . . Mandrell, B. (2014). Aprepitant reduces chemotherapy- induced vomiting in children and young adults with brain tumors. Journal of Pediatric Oncology Nursing, 31 (5), 277-283. doi:10.1177/1043454214531090 Dupuis, L. L., Boodhan, S., Holdsworth, M., Robinson, P. D., Hain, R., Portwine, C., . . . Sung, L.; Pediatric Oncology Group of Ontario. (2013). Guideline for the prevention of acute nausea and vomiting due to antineoplastic medication in pediatric cancer patients. Pediatric Blood and Cancer, 60 (7), 1073-1082. doi:10.1002/pbc.24508 Dupuis, L. L., Robinson, P. D., Boodhan, S., Holdsworth, M., Portwine, C., Gibson, P., . . . Sung, L.; Pediatric Oncology Group of Ontario. (2014). Guideline for the prevention and treatment of anticipatory nausea and vomiting due to chemotherapy in pediatric cancer patients. Pediatric Blood and Cancer, 61 (8), 1506-1512. doi:10.1002/pbc.25063 Dupuis, L. L., Sung, L., Molassiotis, A., Orsey, A. D., Tissing, W. e van de Wetering, M. (2016). 2016 updated MASCC/ESMO consensus recommendations: Prevention of acute chemotherapy-induced nausea and vomiting in children. Supportive Care in Cancer, 26 (1), 323–331. doi:10.1007/s00520-016-3384 Dupuis, L. L., Taddio, A., Kerr, E. N., Kelly, A. e MacKeigan, L. (2006). Development and validation of the pediatric nausea assessment tool for use in children receiving antineoplastic agents. Pharmacotherapy, 26 (9), 1221–1231. doi:10.1592/phco.26.9.1221 Dushenkov, A., Kalabalik, J., Carbone, A. e Jungsuwadee, P. (2017). Drug interactions with aprepitant or fosaprepitant: Review of literature and implications for clinical practice. Journal of Oncology Pharmacy Practice, 23 (4), 296-308. doi:10.1177/1078155216631408 Eilers, J., Harris, D., Henry, K. e Johnson, L. A. (2014). Evidence-based interventions for cancer treatment-related mucositis: Putting evidence into practice. Clinical Journal of Oncology Nursing, 18 (6), 80-96. doi:10.1188/14.CJON.S3.80-96 Eilers, J. e Million, R. (2011). Clinical update: Prevention and management of oral mucositis in patients with cancer . Seminars in Oncology Nursing, 27 (4), e1–e16. doi:10.1016/j.soncn.2011.08.001 Elder, J. J. e Knoderer, H. M. (2015). Characterization of dronabinol usage in a pediatric oncology population. Journal of Pediatric Pharmacology and Therapeutics, 20 (6), 462–467. doi:10.5863/1551-6776-20.6.462
Fasano, R. M. e Josephson, C. D. (2015). Platelet transfusion goals in oncology patients. ASH Hematology, The Education Program, 2015 (1), 462–470. doi:10.1182/asheducation-2015.1.462 Feijen, E. A. M., Leisenring, W. M., Stratton, K. L., Ness, K. K., van der Pal, H. J., Caron, H. N., . . . Chow, E. J. (2015). Equivalence ratio for daunorubicin to doxorubicin in relation to late heart failure in survivors of childhood cancer. Journal of Clinical Oncology, 33 (32), 3774-3780. doi:10.1200/JCO.2015.61.5187 Fernbach, A., Lockart, B., Armus, C. L., Bashore, L. M., Levine, J., Kroon, L., . . . Rodgers, C. (2014). Evidence-based recommendations for fertility preservation options for inclusion in treatment protocols for pediatric and adolescent patients with cancer. Journal of Pediatric Oncology Nursing, 31 (4), 211-222. doi:10.1177/1043454214532025 Filhon, B., Lacarra, B., Hervouet, C., Jaffray, M., Schneider, P. e Vannier, J. P. (2016). Ifosfamide-induced encephalopathy due to a novel formulation of ifosfamide. Pediatric Blood and Cancer, 53 (2), 372- 373. doi:10.1002/pbc.25724 Flank, J., Robinson, P. D., Holdsworth, M., Phillips, R., Portwine, C., Gibson, P., . . . Dupuis, L. L. (2016). Guideline for the treatment of breakthrough and the prevention of refractory chemotherapy- induced nausea and vomiting in children with cancer. Pediatric Blood and Cancer, 63 (7), 1144-1151. doi:10.1002/pbc.25955 Flerlage, J. E. e Baker, J. N. (2015). Methylnaltrexone for opioid- induced constipation in children and adolescents and young adults with progressive incurable cancer at the end of life. Journal of Palliative Medicine, 18 (7), 631–633. doi:10.1089/jpm.2014.0364 Fox, E., Maris, J. M., Widemann, B. C., Meek, K., Goodwin, A., Godspeed, W., . . . Balis, F. M. (2006). A phase 1 study of ABT-751, an orally bioavailable tubulin inhibitor, administered daily for 7 days every 21 days in pediatric patients with solid tumors. Clinical Cancer Research, 12 (16), 4883. Freedman, J. L., Rheingold, S. R. e Fisher, M. J. (2016). Oncologic emergencies. Em P. A. Pizzo e D. G. Poplack (Eds.), Principles and practice of pediatric oncology (7 a ed., pp. 974–975). Filadélfia, PA: Wolters Kluwer. Freyer, D. R., Chen, L., Krailo, M. D., Knight, K., Villaluna, D., Bliss, B., . . . Sung, L. (2017). Effects of sodium thiosulfate versus observation on development of cisplatin-induced hearing loss in children with cancer (ACCL0431): A multicentre, randomised, controlled, open- label, phase 3 trial. The Lancet Oncology, 18 (1) 63–74. doi:10.1016/ S1470-2045(16)30625-8 Fu, C., Gombos, D. S., Lee, J., George, G. C., Hess, K., Whyte, A. e Hong, D. S. (2017). Ocular toxicities associated with targeted anticancer agents: An analysis of clinica data with management suggestions. Oncotarget, 8 (5), 58709–58727. doi:10.18632/oncotarget.17634 Fulbright, J. M. (2011). Review of cardiotoxicity in pediatric cancer patients: During and after therapy. Cardiology Research and Practice, 2011, 942090. doi:10.4061/2011/942090 Garg, R., Agarwala, S. e Bhatnagar, V. (2010). Acute pancreatitis induced by ifosfamide therapy. Journal of Pediatric Surgery, 45 (10), 2071– 2073. doi:10.1016/j.jpedsurg.2010.07.028 George, J. N. e Arnold, D. M. (2017). Drug induced immune thrombocytopenia. T. W. Post (Ed.), UpToDate . Extraído de: https:// www.uptodate.com Gibson, T. M., Ehrhardt, M. J. e Ness, K. K. (2016). Obesity and metabolic syndrome among adult survivors of childhood leukemia. Current Treatment Options in Oncology, 17 (4), 17. doi:10.1007/ s11864-016-0393-5 Goldenberg, I., Moss, A. J. e Zareba, W. (2006). QT interval:
How to measure it and what is “normal.” Journal of Cardiovascular Electrophysiology, 17 (3), 333–336. doi:10.1111/j.1540-8167.2006.00408.x
Goldenberg, N. A., Donadini, M. P., Kahn, S. R., Crowther, M., Kenet, G., Nowak-Göttl, U. e Manco-Johnson, M. J. (2010). Post-thrombotic syndrome in children: A systematic review of frequency of occurrence, validity of outcome measures, and
Capítulo 8. Toxicidade e Tratamento de Sintomas 281
Powered by FlippingBook